Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

  title={Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression},
  author={Francisco Lotufo-Neto and Madhukar H. Trivedi and Michael E. Thase},

Figures and Tables from this paper

Moclobemide: therapeutic use and clinical studies.

  • U. Bonnet
  • Psychology, Medicine
    CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in

Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression

Recent progress in RIMAs toward the treatment of treatment-resistant depression is discussed, with the new class of reversible monoamine oxidase inhibitors (RIMAs) having shown efficacy in depression, with safety and tolerability comparable to SSRIs.

Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients

Moclobemide is an effective antidepressant and is better tolerated than imipramine, a tricyclic antidepressant in the treatment of major depressive disorder.

Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression

This paper reviews the discovery and history of the use of irreversible monoamine oxidase (MAO) inhibitors (MAOIs) such as phenelzine, tranylcypromine and isocarboxazid, as well as the second

Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants

The mechanisms of therapeutic action of MAOIs are discussed, but also the mechanisms explaining their side effects, including hypertensive interactions with dietary tyramine (so-called "cheese reactions") and drug interactions that can lead to hypertensive reactions with some drugs and serotonin toxicities with others.

Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157

CX157 is the first agent in the RIMA class with documented reversible inhibition of human brain MAO-A, supporting its classification as a R IMA, and the first RIM a with observed plasma levels that can serve as a biomarker for the degree of brain MAo-A inhibition.

A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression.

The selegiline transdermal system provides several advantages compared to orally administered MAOIs, including minimal interaction with dietary tyramine and prolonged exposure to the parent compound, while offering a favorable side effect profile.

Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors

Clinicians should familiarize themselves with the properties and indications for the new generation of MAOIs and it is possible that STS may demonstrate benefit in MDD with atypical features or MDD resistant to other antidepressants.

Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.

  • M. Thase
  • Biology
    The Journal of clinical psychiatry
  • 2006
The holy grail of this search for a better MAOI has been identification of a drug that did not require a special diet, has a tolerability and ease-of-use profile comparable to the selective serotonin reuptake inhibitors (SSRIs), and is as effective as tranylcypromine or phenelzine.



Newer and Older Monoamine Oxidase Inhibitors

RIMAs such as moclobemide may become part of the renaissance of MAOIs in the treatment of affective disorders, because of the lack of behavioural toxicity, minimal potentiation for the tyramine pressor response and safety in overdose.

The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.

Using a rat renal nerve preparation, it is demonstrated that acute administration of either moclobemide or brofaromine does not cause a decrease in blood pressure or a significant reduction in sympathetic renal nerve activity, compared with those obtained with clorgyline or desipramine.

Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo

It is concluded that moclobemide may be the second‐generation antidepressant doctors were waiting for, equally effective as the classical antidepressants but far better tolerated.

Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression

  • E. Paykel
  • Psychology
    Acta psychiatrica Scandinavica. Supplementum
  • 1995
The evidence indicates that moclobemide is effective in typical severe depression with melancholia rather than being limited to less lypical subtypes.

A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.

It was concluded that (-)-deprenyl is an effective antidepressant in a dose range where it is distinguished by the absence of many of the side effects typical of nonselective MAO inhibitors.

Double-blind comparison of moclobemide and tranylcypromine in depression.

Both treatments resulted in significant amelioration of depression as determined by all rating instruments, and the tolerability of both drugs was good, although moclobemide appeared to possess a small advantage in this regard.

Efficacy of a reversible monoamine oxidase‐A inhibitor versus imipramine in subgroups of depressed patients

The conclusion from the 2 studies is that, contrary to what is frequently stated for monoamine oxidase inhibitors, moclobemide appears as effective as a tricylic in treating endogenous depression.

Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients

Clinical studies show that, in elderly depressed patients, moclobemide is at least as effective as other antidepressants, and is as well tolerated in elderly people as in younger people.

Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression

The design and the main therapeutic results of 3 controlled double‐blind studies comparing moclobemide with tricyclics and/or placebo in depressed patients are presented and it is shown that reversible inhibitors of MAO‐A demonstrate good efficacy independently of the diagnostic category of depression.

Monoamine Oxidase Inhibitors Phenelzine and Brofaromine Increase Plasma Serotonin and Decrease 5‐Hydroxyindoleacetic Acid in Patients with Major Depression: Relationship to Clinical Improvement

The consistent relationship the authors found between the biochemical and clinical changes again suggests and supports a key role of 5-HT in the antidepressant effect of these MAO inhibitors.